H.C. Wainwright raised the firm’s price target on Lipocine (LPCN) to $15 from $7 and keeps a Buy rating on the shares. The firm says LPCN 1154 showed a favorable safety profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN:
- Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug
- Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154
- Lipocine updates investor presentation and corporate materials
- Lipocine Advances Phase 3 Postpartum Depression Drug Trial
- Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned